As an early career electrophysiologist, Richard I. Fogel, MD, learned to raise his hand when projects needed a captain. Now he’s CEO of the St. Vincent Medical Group in Indianapolis and president of the Heart Rhythm Society (HRS). His formula? Listen, ask good questions, surround yourself with talented people and let them do their jobs, he explains in a Q&A with Cardiovascular Business.

Preregistration attendance for Heart Rhythm Society 2014 has increased significantly compared with last year in all demographic categories, said John D. Day, MD, chair of the scientific session program committee, with notable bumps in international physicians and allied professionals.

A subcommittee of the Heart Rhythm Society (HRS) published a list of five treatments and procedures electrophysiologists should avoid in patients with arrhythmias. The five “don’ts” are available on the HRS website.

Today, members of the Heart Rhythm Society (HRS) are visiting 35 congressional offices on Capitol Hill to raise visibility and support for two proposals: the “Medicare Program Integrity Improvement and Education Act” and the “Teaching Children to Save Lives Act.” HRS is advocating for the support of these two bills because both intend to deliver outcomes aligned with the Society’s mission to improve the care of patients by advancing research, education and optimal health care policies and standards. 

Hugh Calkins, MD, FHRS, CCDS, was named the president of the Heart Rhythm Society (HRS) during the 34th Annual Scientific Sessions, held in Denver last week.  Announced during the Presidents’ Reception on Friday, May 10th, Dr. Calkins now serves as the 35th president of HRS, making Anne M. Gillis, MD, FHRS, the immediate past president. Dr. Calkins is currently a Nicholas J. Fortuin Professor of Cardiology and Professor of Medicine at the Johns Hopkins University School of Medicine in Baltimore, Maryland.  

Seven percent of patients implanted with subcutaneous implantable cardioverter-defibrillators (S-ICDs) experienced inappropriate shocks, according to an analysis of registry data presented May 9 at the Heart Rhythm Society (HRS) scientific sessions in Denver.

The Watchman wait may be over. An analysis of long-term data found the Watchman left atrial appendage closure device to be superior to warfarin for primary efficacy and mortality.

Patients with paroxysmal atrial fibrillation (AF) were less likely to receive guideline recommended anticoagulation therapy compared with persistent AF patients. The analysis presented May 8 at the Heart Rhythm Society scientific sessions in Denver included registry data on more than 62,000 patients.